Optimal prevention of seizures induced by high-dose busulfan

Pharmacotherapy

Volumn 28, Issue 12, 2008, Pages 1502-1510

  Eberly, Andrea L ^a   Anderson, Gail D ^a   Bubalo, Joseph S ^c   McCune, Jeannine S ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antiepileptic drugs; Benzodiazepines; Busulfan; Drug interactions; HCT; Hematopoietic cell transplantation; Phenytoin; Seizure prophylaxis; Seizures

Indexed keywords

ANTICONVULSIVE AGENT; BUSULFAN; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; DIAZEPAM; ETIRACETAM; GLUTATHIONE TRANSFERASE A1; GLUTATHIONE TRANSFERASE P1; LAMOTRIGINE; LORAZEPAM; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ACUTE LEUKEMIA; ALKALINE PHOSPHATASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANTICONVULSANT THERAPY; APLASTIC ANEMIA; AREA UNDER THE CURVE; ATAXIA; BILIRUBIN BLOOD LEVEL; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CHRONIC MYELOID LEUKEMIA; CONTINUOUS INFUSION; COORDINATION DISORDER; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FEVER; FOOD AND DRUG ADMINISTRATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERSENSITIVITY REACTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LENNOX GASTAUT SYNDROME; LEUKOPENIA; LIVER TOXICITY; MEGALOCYTOSIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PHARMACOGENOMICS; PROPHYLAXIS; RASH; REDUCED INTENSITY CONDITIONING; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; THROMBOCYTOPENIA; TONIC CLONIC SEIZURE; TREATMENT DURATION; VOMITING;

EID: 57149109783     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.12.1502     Document Type: Review

References (79)

1. Deeg HJ, Maris MB, Scott BL, Warren EH. Optimization of allogeneic transplant conditioning: not the time for dogma. Leukemia 2006;20:1701-5.
2. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006;354:1813-26.
3. Kletzel M, Jacobsohn D, Duerst R. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:472-9.
4. Ott MG, Schmidt M, Schwarzwaelder K, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9.
5. Aiuti A, Slavin S, Aker M, et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002;296:2410-13.
6. Meyers G, Dunn A, Kovascovics TJ, et al. Busulfan, fludarabine, and total body irradiation followed by allogeneic peripheral blood stem cell transplantation is an effective treatment for hematologic malignancies with acceptable toxicities in a high risk population [abstract 318]. Biol Blood Marrow Transplant 2008;14(2 suppl 2):I17.
7. Marcus RE, Goldman JM. Convulsions due to high-dose busulphan [case report]. Lancet 1984;2:1463.
8. Hartmann O, Benhamou E, Beaujean F, et al. High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 1986;4:1804-10.
9. Vassal G, Deroussent A, Hartmann O, et al. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res 1990;50:6203-7.
10. Murphy CP, Harden EA, Thompson JM. Generalized seizures secondary to high-dose busulfan therapy. Ann Pharmacother 1992;26:30-1.
11. Meloni G, Raucci U, Pinto RM, Spalice A, Vignetti M, Iannetti P. Pretransplant conditioning with busulfan and cyclophosphamide in acute leukemia patients: neurological and electroencephalographic prospective study. Ann Oncol 1992;3: 145-8.
12. Meloni G, Nasta L, Pinto RM, Spalice A, Raucci U, Iannetti P. Clonazepam prophylaxis and busulfan-related myoclonic epilepsy in autografted acute leukemia patients. Haematologica 1995;80:532-4.
13. Kobayashi R, Watanabe N, Iguchi A, et al. Electroencephalogram abnormality and high-dose busulfan in conditioning regimens for stem cell transplantation. Bone Marrow Transplant 1998;21:217-20.
14. La Morgia C, Mondini S, Guarino M, Bonifazi F, Cirignotta F. Busulfan neurotoxicity and EEG abnormalities: a case report. Neurol Sci 2004;25:95-7.
15. Hassan M, Ehrsson H, Smedmyr B, et al. Cerebrospinal fluid and plasma concentrations of busulfan during high-dose therapy. Bone Marrow Transplant 1989;4:113-14.
16. Sureda A, Perez de Oteyza J, Garcia Larana J, Odriozola J. High-dose busulfan and seizures. Ann Intern Med 1989;I11: 543-4.
17. Peters WP, Henner WD, Grochow LB, et al. Clinical and pharmacologic effects of high-dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 1987;47:6402-6.
18. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007;13: 853-62.
19. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:167-73.
20. Radich JP, Gooley T, Bensinger W et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31-5.
21. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-60.
22. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
23. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000;39:155-65.
24. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996;24:1015-19.
25. Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 2002;41:93-103.
26. 2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat. J Pharmacol Exp Ther 2004;308:1204-12.
27. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997;57:4229-35.
28. Beringer PM, Slaughter RL. Transporters and their impact on drug disposition. Ann Pharmacother 2005;39:1097-108.
29. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20(suppl 1):S1-56.
30. Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005;7(suppl 1):S1-64.
31. Polycarpou A, Papanikolaou P, Ioannidis JP, Contopoulos-Ioannidis DG. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev 2005(3):CD005064.
32. Ntais C, Pakos E, Kyzas P, Ioannidis JP. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev 2005(3): CD005063.
33. Michelucci R. Optimizing therapy of seizures in neurosurgery. Neurology 2006;67(12 suppl 4):S14-18.
34. Brathen G, Ben-Menachem E, Brodtkorb E, et al. European Federation of Neurological Sciences (EFNS) guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force. Eur J Neurol 2005;12:575-81. (Erratum in Eur J Neurol 2005;12:816.)
35. Holmes GL. Carbamazepine: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002: 285-97.
36. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007;27:1425-39.
37. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother 1998;32:554-63.
38. European Medicines Agency. Scientific discussion, 2005. Available from http://www.emea.europa.eu//humandocs/ PDFs/EPAR/busilvex/168603en6.pdf. Accessed September 26, 2008.
39. Genton P, Gelisse P. Valproic acid: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002: 837-51.
40. Allan RW. Myelodysplastic syndrome associated with chronic valproic acid therapy: a case report and review of the literature. Hematology 2007;12:493-6.
41. Baulac M, Cramer JA, Mattson RH. Phenobarbital and other barbiturates: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:528-40.
42. Davies MH, Schnell RC. Comparison of basal glutathione S-transferase activities and of the influence of phenobarbital, butylated hydroxy-anisole or 5,5′-diphenylhydantoin on enzyme activity in male rodents. Comp Biochem Physiol C 1987;88:91-3.
43. Grigg AP, Shepherd JD, Phillips GL. Busulphan and phenytoin. Ann Intern Med 1989;111:1049-50.
44. Atra A, Whelan JS, Calvagna V, et al. High-dose busulphan/melphalan with autologous stem cell rescue in Ewing's sarcoma. Bone marrow transplant 1997;20:843-6.
45. Chang BS, Lowenstein DH. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2003;60:10-16.
46. Beelen DW, Quabeck K, Graeven U, Sayer HG, Mahmoud HK, Schaefer UW. Acute toxicity and first clinical results of intensive postinduction therapy using a modified busulfan and cyclophosphamide regimen with autologous bone marrow rescue in first remission of acute myeloid leukemia. Blood 1989;74:1507-16.
47. Buggia I, Locatelli F, Regazzi MB, Zecca M. Busulfan. Ann Pharmacother 1994;28:1055-62.
48. Wilder BJ, Bruni J. Phenytoin and other hydantoins: clinical efficacy and use in epilepsy. In: Levy R, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott, Williams & Wilkins, 2002:591-6.
49. Bruni J. Phenytoin and other hydantoins: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott, Williams & Wilkins, 2002:605-10.
50. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9.
51. Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J Clin Oncol 1996;14:1484-94.
52. de Jonge ME, Huitema AD, van Dam SM, Beijnen JH, Rodenhuis S. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 2005;55:507-10.
53. Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 1990;27:226-8.
54. Gallagher EP, Sheehy KM. Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol Sci 2001;59(1): 118-26.
55. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993;33: 181-6.
56. Sandstrom M, Karlsson MO, Ljungman P, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant 2001;28:657-64.
57. Aggarwal C, Gupta S, Vaughan WP, et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006;12:770-7.
58. Madden T, de Lima M, Thapar N, et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007;13:56-64.
59. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006;57:191-8.
60. Coles BF, Morel F, Rauch C, et al. Effect of polymorphism in the human glutathione S-transferase A1 promoter on hepatic GSTA1 and GSTA2 expression. Pharmacogenetics 2001;11: 663-9.
61. Srivastava A, Poonkuzhali B, Shaji RV, et al. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004;104:1574-7.
62. Tibussek D, Distelmaier F, Schonberger S, Gobel U, Mayatepek E. Antiepileptic treatment in paediatric oncology: an interdisciplinary challenge. Klin Padiatr 2006;218:340-9.
63. Singh G, Rees JH, Sander JW. Seizures and epilepsy in oncological practice: causes, course, mechanisms and treatment. J Neurol Neurosurg Psychiatry 2007;78:342-9.
64. Schwarer AP, Opat SS, Watson AL, Cole-Sinclair MF. Clobazam for seizure prophylaxis during busulfan chemotherapy [case report]. Lancet 1995;346:1238.
65. Zwaveling J, Bredius RG, Cremers SC, et al. Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005;35:17-23.
66. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994;84:2357-62.
67. Chan KW, Mullen CA, Worth LL, et al. Lorazepam for seizure prophylaxis during high-dose busulfan administration. Bone Marrow Transplant 2002;29:963-5.
68. Bubalo JS, Kovascovics TJ, Meyers G, et al. Clonazepam and levetiracetam for prevention of busulfan-induced seizures: a single-center experience [abstract]. Biol Blood Marrow Transplant 2008;14(2 suppl 2):abstract 467.
69. Anderson G, Miller J. Benzodiazepines: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:187-205.
70. Michelucci R, Tassinari, CA. Benzodiazepines: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:215-23.
71. Klotz U. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet 2007;46:271-9.
72. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;43:763-80.
73. Manaka S, Ishijima B, Mayanagi Y. Postoperative seizures: epidemiology, pathology, and prophylaxis. Neurol Med Chir (Tokyo) 2003;43:589-600.
74. Lee BI. Zonisamide: adverse effects. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:892-8.
75. Mather G, Shah J. Zonisamide: drug interactions. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs, 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:880-4.
76. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61:246-55.
77. Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402-8.
78. UCB Inc. Keppra (levetiracetam) package insert. Smyrna, GA; 2008.
79. Otoul C, De Smedt H, Stockis A. Lack of pharmacokinetic interaction of levetiracetam on carbamazepine, valproic acid, topiramate, and lamotrigine in children with epilepsy. Epilepsia 2007;48:2111-15.